The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 26, 2021
Filed:
Aug. 28, 2015
Applicant:
Medtronic Ardian Luxembourg S.a.r.l., Luxembourg, LU;
Inventors:
Carol Sullivan, Santa Rosa, CA (US);
Stefan Tunev, Santa Rosa, CA (US);
Assignee:
MEDTRONIC ARDIAN LUXEMBOURG S.A.R.L., Luxembourg, LU;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61B 5/00 (2006.01); A61B 5/20 (2006.01); A61B 10/00 (2006.01); A61N 1/36 (2006.01); A61N 1/05 (2006.01); A61B 18/14 (2006.01); A61B 18/00 (2006.01); G01N 33/493 (2006.01); G01N 33/53 (2006.01); G01N 33/94 (2006.01); G01N 33/74 (2006.01); A61B 5/0538 (2021.01); A61B 5/145 (2006.01); A61B 5/24 (2021.01);
U.S. Cl.
CPC ...
A61N 1/3605 (2013.01); A61B 5/201 (2013.01); A61B 5/207 (2013.01); A61B 5/4848 (2013.01); A61B 10/007 (2013.01); A61B 18/1492 (2013.01); A61N 1/0551 (2013.01); A61N 1/36121 (2013.01); G01N 33/493 (2013.01); A61B 5/0538 (2013.01); A61B 5/14507 (2013.01); A61B 5/24 (2021.01); A61B 5/4035 (2013.01); A61B 5/4041 (2013.01); A61B 2018/0022 (2013.01); A61B 2018/00267 (2013.01); A61B 2018/00345 (2013.01); A61B 2018/00404 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00511 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00702 (2013.01); A61B 2018/00875 (2013.01); A61B 2218/002 (2013.01); A61N 1/36117 (2013.01); G01N 33/5308 (2013.01); G01N 33/74 (2013.01); G01N 33/9433 (2013.01); G01N 2800/347 (2013.01); G01N 2800/52 (2013.01);
Abstract
Provided herein are methods, devices and compositions for assessing neuromodulation efficacy based on changes in the level of one or more biomarkers in plasma or urine collected from a human subject following a renal neuromodulation procedure.